🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

JenaValve is unveiling important clinical results from the ALIGN-AR Trial in a Late-Breaking Clinical Trials session. Join us at #ACC25 on Sunday, March 30th to be part of the conversation! Don't miss the opportunity to explore innovations in transcatheter valve technology that

Breaking news from #ACC25! Join us for a Late-Breaking Clinical Trials session as Dr. Raj Makkar presents clinical outcomes from 500 patients treated in ALIGN-AR—the first pivotal study evaluating a dedicated TAVR device for severe aortic regurgitation in high-risk patients.

Late breaking presentation from #ACC25! Jenavalve presents outcomes from the first 500 patients in the ALIGN-AR Trial, marking the largest, prospective study of a dedicated TAVR device in patients with severe aortic regurgitation. Don’t miss the details in our latest press

🇨🇦 Breaking new ground in Montreal, Canada! 🇨🇦 We're proud to share that the first ever Trilogy cases have been completed in Canada! A huge thank you to the pioneering heart teams at Montreal Heart Institute for their dedication and expertise in making this possible. This

Quantification of aortic regurgitation by echo is complex! Insights from the experts can make all the difference. Tune in April 10th, for part 2 of this important webinar series from American Society of Echocardiography . 🗓️Register now: bit.ly/4hDGtjT #AorticRegurgitation #echocardiography

From #ACC25, as presented by Raj Makkar - in 500 patients enrolled in the ALIGN-AR trial (PMA + continued access), the primary safety and efficacy outcomes achieved performance goals, consistent with what we reported in the initial 180 patient PMA study. Thank you to all the

🎓 Don’t miss Part 2 this important webinar from American Society of Echocardiography! “The Evolving Role of Echocardiography in Aortic Regurgitation” dives into the complexities of accurately diagnosing AR severity by echocardiography — a common and often challenging issue in clinical practice. Register

Live Educational Session | The American Society of Echocardiography will be hosting an X-exclusive deep dive discussion on the evolving landscape of Aortic Regurgitation management. This session will complement the recent JASE review "Noninvasive Imaging for Native Aortic Valve Regurgitation" which

Presented at #GulfPCR! This recorded case showcases Trilogy implantation in an LVAD ❤️ patient with severe aortic regurgitation (AR) 🔄. Watch the expert approach to tackling this complex case! Jump to ▶️ 1:11:30 to see the JenaValve case in action! 👀🔬 bit.ly/4jeWoGN

📣Don't Miss Out! Tomorrow is the night — the American Society of Echocardiography Live Journal Club Session will be taking a deep dive into the evolving management of Aortic Regurgitation, with a focus on the critical role of echocardiography in accurate assessment and clinical decision-making. 📅

📍Seattle-bound! We are excited to attend #AATS2025 and engage with the cardiothoracic surgery community. We look forward to insightful discussions on the evolving role of TAVR for aortic regurgitation and how it impacts surgical practice. #AATS2025 #TAVR

JenaValve is thrilled to be exhibiting at #AATS2025! 📍Visit us at Booth #626 (next to Theater #2) to learn about the ARTIST trial—a randomized study comparing TAVR with our Trilogy THV System to SAVR in patients with symptomatic, severe aortic regurgitation. 👨

Calling all interventional cardiology fellows! Join us in Miami, FL at the 2025 Cardiovascular Research Foundation Fellows Course for the Academic Satellite Program: 🫀 A Step Forward in the Evolution of TAVR: TAVR for Aortic Regurgitation 📍 Room: Coral 2 | Level 2 | Coastal Convention Center,

We're heading to Paris, France for #EuroPCR2025! Visit us at Booth #M15 (Level 2) to learn how we're advancing transcatheter solutions for Aortic Regurgitation with the Trilogy Heart Valve System--the only TAVI valve CE Mark approved for AR. Don't miss the chance to connect

🎉Milestone Moment in Mainz, Germany!💯 We’re thrilled to celebrate 100 Trilogy valves implanted at Universitätsmedizin Mainz ! This achievement marks meaningful progress in offering transcatheter options for patients with severe aortic regurgitation. Thank you to the team Mainz for

The role of TAVI is expanding beyond aortic stenosis. Join us at EuroPCR to explore the latest data and expert perspectives on emerging indications of TAVR including aortic regurgitation. 📍Room Maillot 📅 Thursday, May 22nd 🕙 4:15 PM (CEST) PCRonline 🫀 #TAVI #EuroPCR

We're here at #EuroPCR! Come visit the JenaValve team on the second floor, next to Room Maillot — we’re excited to connect and share the latest on transcatheter solutions for aortic regurgitation. See you soon! 👋🫀 #EuroPCR #TAVI #JenaValve #Trilogy

🫀 Advancing Structural Heart Care in Pennsylvania! JenaValve is excited to participate in @Allegheny Health Network’s 25th Annual Cardiovascular Disease Symposium, joining physicians from across Pennsylvania to discuss new innovations and approach to cardiovascular disease.